Table 2.
Global response at end of treatment among severely ill patients and the various subpopulations
| Patient group | Global response at end of treatment | ||||
|---|---|---|---|---|---|
| Anidulafungin | Fluconazole | P value | Absolute difference (95% CI) | ||
| n (%) | |||||
| Moderate to severe illness | Success | 63/89 (70.8) | 40/74 (54.1) | 0.034 | 16.7% (2.0, 31.5) |
| Failure | 26/89 (29.2) | 34/74 (45.9) | |||
| APACHE II ≥ 15 | Success | 43/63 (68.3) | 23/50 (46.0) | 0.022 | 22.3% (4.3, 40.2) |
| Failure | 20/63 (31.7) | 27/50 (54.0) | |||
| Severe sepsis with ≥ 1 organ dysfunction | Success | 42/62 (67.7) | 29/56 (51.8) | 0.092 | 16.0% (-1.6, 33.5) |
| Failure | 20/62 (32.3) | 27/56 (48.2) | |||
| Respiratory dysfunction | Success | 16/22 (72.7) | 7/22 (31.8) | 0.015 | 40.9% (14.0, 67.8) |
| Failure | 6/22 (27.3) | 15/22 (68.2) | |||
| Renal dysfunction | Success | 26/36 (72.2) | 18/33 (54.5) | 0.142 | 17.7% (-4.7, 40.1) |
| Failure | 10/36 (27.8) | 15/33 (45.5) | |||
| Hepatic dysfunction | Success | 13/18 (72.2) | 7/16 (43.8) | 0.163 | 28.5% (-3.4, 60.4) |
| Failure | 5/18 (27.8) | 9/16 (56.3) | |||
| Cardiovascular dysfunction | Success | 6/13 (46.2) | 8/20 (40.0) | 1.000 | 6.2% (-28, 40.7) |
| Failure | 7/13 (53.8) | 12/20 (60.0) | |||
| Severe sepsis with multiple organ dysfunction | Success | 16/21 (76.2) | 7/24 (29.2) | 0.003 | 47.0% (21.3, 72.8) |
| Failure | 5/21 (23.8) | 17/24 (70.8) | |||
| Treatment in ICU | Success | 24/35 (68.6) | 13/28 (46.4) | 0.122 | 22.1% (-1.9, 46.2) |
| Failure | 11/35 (31.4) | 15/28 (53.6) | |||